Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX stock is upgraded to hold.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster manufacturing, shaking up the $150-bn obesity market ...

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

without meaningful change in near-term strategy, we continue to see a more difficult path forward," he said. Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar ...